检索结果 - Martin H. Voss

Refine Results
  1. 1
    mTOR Inhibitors in Advanced Renal Cell Carcinoma

    mTOR Inhibitors in Advanced Renal Cell Carcinoma 由 Martin H. Voss, Ana M. Molina, Robert J. Motzer

    出版 2011
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma

    Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma 由 Maria I. Carlo, Martin H. Voss, Robert J. Motzer

    出版 2016
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

    Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma 由 Kyrollis Attalla, Stanley Weng, Martin H. Voss, A. Ari Hakimi

    出版 2020
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma

    Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma 由 Lynda Vuong, Ritesh R. Kotecha, Martin H. Voss, A. Ari Hakimi

    出版 2019
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events 由 Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    出版 2020
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-Cell Lymphoma: A Single Institution Experience

    Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-Cell... 由 Martin H. Voss, Matthew A. Lunning, Jocelyn Maragulia, Esperanza B. Papadopoulos, Jeffrey L. Goldberg, Andrew D. Zelenetz, Steven M. Horwitz

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

    Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma 由 Martin H. Voss, David Chen, Mahtab Marker, A. Ari Hakimi, Chung‐Han Lee, James J. Hsieh, Jennifer J. Knox, Maurizio Voi, Robert J. Motzer

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

    Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma 由 Ana M. Molina, Darren R. Feldman, Martin H. Voss, Michelle S. Ginsberg, Michael Baum, Dion R. Brocks, Patricia M. Fischer, M. J. Trinos, Sujata Patil, Robert J. Motzer

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies

    Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies 由 Martin H. Voss, Diogo Assed Bastos, Christoph Karlo, Albulena Ajeti, A. Ari Hakimi, Darren R. Feldman, Jia‐Juan Hsieh, Ana M. Molina, Sujata Patil, Robert J. Motzer

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study

    Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study 由 Martin H. Voss, Albert Reising, Yuan Cheng, Parul Patel, Mahtab Marker, Fengshen Kuo, Timothy A. Chan, Toni K. Choueiri, James J. Hsieh, A. Ari Hakimi, Robert J. Motzer

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

    A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma 由 Maria I. Carlo, Ana M. Molina, Yulia Lakhman, Sujata Patil, Kaitlin M. Woo, John DeLuca, Chung‐Han Lee, James J. Hsieh, Darren R. Feldman, Robert J. Motzer, Martin H. Voss

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups

    Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups 由 Guillermo de Velasco, Diana Miao, Martin H. Voss, A. Ari Hakimi, James J. Hsieh, Nizar M. Tannir, Pheroze Tamboli, Leonard J. Appleman, W. Kimryn Rathmell, Eliezer M. Van Allen, Toni K. Choueiri

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes

    Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes 由 Yasser Ged, Ying‐Bei Chen, Andrea Knežević, Mark T.A. Donoghue, Maria I. Carlo, Chung‐Han Lee, Darren R. Feldman, Sujata Patil, A. Ari Hakimi, Paul Russo, Martin H. Voss, Robert J. Motzer

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

    Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with me... 由 Rosa Nadal, A. Amin, Daniel M. Geynisman, Martin H. Voss, Matthew Weinstock, Jaime Doyle, Zhi Zhang, A. Viúdez, Elizabeth R. Plimack, David F. McDermott, Robert J. Motzer, Brian I. Rini, Hans J. Hammers

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade

    Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade 由 Jason Beattie, Hira Rizvi, Paige Fuentes, Jia Luo, Adam J. Schoenfeld, I‐Hsin Lin, Michael A. Postow, Margaret K. Callahan, Martin H. Voss, Neil J. Shah, Allison Betof Warner, Mohit Chawla, Matthew D. Hellmann

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer

    Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer 由 Ying‐Bei Chen, A. Rose Brannon, Antoun Toubaji, Mária Dudás, Helen Won, Hikmat Al‐Ahmadie, Samson W. Fine, Anuradha Gopalan, Norma Frizzell, Martin H. Voss, Paul Russo, Michael F. Berger, Satish K. Tickoo, Victor E. Reuter

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes

    Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes 由 Yasser Ged, Ying‐Bei Chen, Andrea Knežević, Jozefina Casuscelli, Almedina Redzematovic, Renzo G. DiNatale, Maria I. Carlo, Chung‐Han Lee, Darren R. Feldman, Sujata Patil, A. Ari Hakimi, Paul Russo, Robert J. Motzer, Martin H. Voss

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

    A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer 由 James J. Harding, Andrew X. Zhu, Todd M. Bauer, Toni K. Choueiri, Alexander Drilon, Martin H. Voss, Charles S. Fuchs, Ghassan K. Abou‐Alfa, Sameera R. Wijayawardana, Xuejing Aimee Wang, Brian A. Moser, Arantxa Uruñuela, Volker Wacheck, Johanna C. Bendell

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma

    Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma 由 A. Ari Hakimi, Ying‐Bei Chen, James Wren, Mithat Gönen, Omar Abdel‐Wahab, Adriana Heguy, Han Liu, Shugaku Takeda, Satish K. Tickoo, Victor E. Reuter, Martin H. Voss, Robert J. Motzer, Jonathan Coleman, Emily H. Cheng, Paul Russo, James J. Hsieh

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i>: A Report by MSKCC and the KIRC TCGA Research Network

    Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i>: A Report by MSKCC and the KIRC TCGA Research Network 由 A. Ari Hakimi, Irina Ostrovnaya, Boris Reva, Nikolaus Schultz, Ying‐Bei Chen, Mithat Gönen, Han Liu, Shugaku Takeda, Martin H. Voss, Satish K. Tickoo, Victor E. Reuter, Paul Russo, Emily H. Cheng, Chris Sander, Robert J. Motzer, James J. Hsieh

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: